USOO96.03826B2 (12) United States Patent (10) Patent No.: US 9,603,826 B2 Soni (45) Date of Patent: Mar. 28, 2017 (54) METHODS OF REDUCING THE RISK OF A 5,618,558 A 4/1997 Horrobin et al. CARDOVASCULAREVENT IN A SUBJECT 5,656,667 A 8, 1997 Breivik et al. 5,698,594 A 12/1997 Breivik et al. ON STATIN THERAPY 5,760,081 A 6/1998 Leaf et al. 5,776,978 A 7/1998 Bruzzese (71) Applicant: Amarin Pharmaceuticals Ireland 5,792,795. A 8, 1998 Buser et al. Limited, Dublin (IE) 5,837,731 A 11/1998 Vaddadi 5,840,944 A 11/1998 Furihata et al. 5,886,037 A 3, 1999 Klor et al. (72) Inventor: Paresh Soni, Mystic, CT (US) 5,888,541 A 3, 1999 Horrobin et al. 5.948,818 A 9, 1999 Buser et al. (73) Assignee: AMARIN PHARMACEUTICALS 6,025,008 A 2/2000 Akahoshi IRELAND LIMITED, Dublin (IE) 6,069,168 A 5, 2000 Horrobin et al. 6,193.999 B1 2/2001 Gennadios (*) Notice: Subject to any disclaimer, the term of this 6,284,268 B1 9, 2001 Mishra et al. 6,313,330 B1 11/2001 Kiyohara et al. patent is extended or adjusted under 35 6,326,031 B1 12/2001 Hsia et al. U.S.C. 154(b) by 0 days. 6,326,355 B1 12/2001 Abbruzzese et al. 6,331,568 B1 12/2001 Horrobin (21) Appl. No.: 14/411,815 6,368,621 B1 4/2002 Engel et al. 6,384,077 B1 5, 2002 Peet (22) PCT Fed: Jun. 28, 2013 6.479,544 B1 1 1/2002 Horrobin 6,531,150 B1 3/2003 Sunohara et al. (86) PCT No.: PCT/US2013/048.559 (Continued) FOREIGN PATENT DOCUMENTS S 371 (c)(1), (2) Date: Dec. 29, 2014 CA 2628.305 5/2007 CA 2653787 12/2007 (87) PCT Pub. No.: WO2O14/OOSO13 (Continued) PCT Pub. Date: Jan. 3, 2014 OTHER PUBLICATIONS Prior Publication Data Ethyl eicosapentaenoic acid online), retrieved on Dec. 11, 2015 (65) Retrieved from the Internet, URL: http://en.wikipedia.org/wiki/ US 2015/O157592 A1 Jun. 11, 2015 Ethyl eicosapentaenoic acid. Ethyl icosapentate online), retrieved on Dec. 11, 2015 Retrieved from the Internet, URL: http://www.chemspider.com/Chemical Related U.S. Application Data Structure.4445394.html. A study of AMR101 to evaluate its ability to reduce cardiovascular (60) Provisional application No. 61/666.447, filed on Jun. events in high risk patients with hypertriglyceridemia and on statin 29, 2012. (REDUCE-IT). Available at: http://clinicaltrials.gov/show? NCTO 1492361. (51) Int. C. Aarsland, et al., “On the Effect of Peroximsomal beta-Oxidation and A6 IK 3L/232 (2006.01) Carnitine Palmitoyltransferase Activity by Eicosapentaenoic Aid in Live and Heart of Rats.” Lipids, 25:546-548, (1990). A 6LX 3L/397 (2006.01) Aas, V., et al., “Eicosapentaenoic acid (20:5 n-3) increases fatty acid A6 IK 45/06 (2006.01) and glucose uptake in cultured human skeletal muscle cells.” (52) U.S. C. Journal of Lipid Research, 47:366-374 (2006). CPC .......... A6 IK3I/232 (2013.01); A61K 3 1/397 Abbey, M., et al., “Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activ (2013.01); A61K 45/06 (2013.01) ity in humans' Arterioscler. Thromb. Vasc. Biol. 10:85-94 (1990). (58) Field of Classification Search Abela GS, Aziz K. Cholesterol crystals cause mechanical damage to CPC ..... A61K 31/232; A61K 45/06; A61K 3 1/397 biological membranes: a proposed mechanism of plaque rupture and See application file for complete search history. erosion leading to arterial thrombosis. Clin. Cardiol. 2005:28(9):413-420. References Cited Abelo A, Andersson TB, Antonsson M, et al. Stereoselective (56) metabolism of omeprazole by human cytochrome P450 enzymes. U.S. PATENT DOCUMENTS Drug Metab. Dispos. Aug. 28, 2000 (8): 966-72. (Continued) 4,377,526 A 3/1983 Fujita et al. 4,526,902 A 7, 1985 Rubin Primary Examiner — Kristin Vajda 4,920,098 A 4, 1990 Cotter et al. (74) Attorney, Agent, or Firm — Perkins Coie LLP 4,935,243 A 6, 1990 Borkan et al. 5,013,443 A 5/1991 Higashidate et al. (57) ABSTRACT 5,116,871 A 5, 1992 Horrobin et al. In various embodiments, the present invention provides 5,178,873 A 1/1993 Horrobin et al. methods of reducing the risk of a cardiovascular event in a 5, 198,468 A 3, 1993 Horrobin Subject on statin therapy and, in particular, a method of 5,215,630 A 6, 1993 Hata et al. reducing the risk of a cardiovascular event in a Subject on 5,252.333 A 10, 1993 Horrobin statin therapy having a fasting baseline triglyceride level of 5,343,389 A 8, 1994 OtvOS about 135 mg/dL to about 500 mg/dL, and administering to 5,457,130 A 10, 1995 Tisdale et al. the Subject a pharmaceutical composition comprising about 5,502,077 A 3, 1996 Breivik et al. 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a 5,567,730 A 10/1996 Miyashita et al. derivative thereof. 5,589,508 A 12/1996 Schlotzer et al. 5,603,959 A 2f1997 Horrobin et al. 13 Claims, No Drawings US 9,603,826 B2 Page 2 (56) References Cited 2006/0172012 A1 8/2006 Finley et al. 2006/0189682 A1 8/2006 Payne et al. U.S. PATENT DOCUMENTS 2006/0211749 A1 9, 2006 Bobotas et al. 2006/0211761 A1 9/2006 Kumar Yatendra et al. 6,555,700 B1 4/2003 Horrobin et al. 2006/0211762 A1 9/2006 Rongen 6,620.821 B2 9, 2003 Rob 2006/0211763 A1 9/2006 Fawzy et al. 6,685813 B2 2/2004 Peet 2006/0217356 A1 9/2006 Wright et al. 6.846,942 B2 1/2005 Rubin 2006/0252833 A1 11, 2006 Peet et al. 7032.713 B2 4/2006 Aoki et al. 2007/0021504 A1 1/2007 Yokoyama et al. 7I12,609 B2 92006 Hemelinet al. 2007/0060532 A1 3/2007 Junien et al. 7, 1918 B2 10/2006 Peet 2007/0104779 A1 5/2007 Rongen et al. 7,498.359 B2 3/2009 Yokoyama et al. 2007/0105954 Al 5/2007 Puri 7,511,131 B2 3/2009 Crooke et al. 2007/O141138 A1 6/2007 Feuerstein et al. 7.598.227 B2 10, 2009 Crooke et al. 2007/016752O A1 7/2007 Bruzzese 7776,881 B2 & 2010 Aoki et al. 2007/0185198 A1 8/2007 Yokoyama et al. 8.188146 B2 5 2012 Peetet al. 2007/0191467 A1 8/2007 Rongen et al. 8,393,727 B2 10/2012 Manku et al. 2007/0202159 A1 8, 2007 Mathur et al. 8.293.728 B2 0/2012 Manku et al. 2007/0212411 A1 9/2007 Fawzy et al. 8.298,554 B2 0/2012 Manku 2007/0219271 A1 9, 2007 Mittmann et al. 8.314,086 B2 1/2012 Manku et al. 2007,0265340 A1 11/2007 Shallwitz et al. 83875 B2 1/2012 Manku et al. 2007,0269.507 A1 11/2007 Sachetto et al. 8.324.195 B2 12/2012 Manku et al. 2008/0020018 A1 1/2008 Moodley et al. 8,357,677 B1 1/2013 Manku et al. 2008/0085911 A1 4/2008 Rongen et al. 8.367.652 B2 2/2013 Manku et al. 2008.0089876 A1 4/2008 Cavazza 8377,920 B2 2/2013 Manku et al. 2008.0113046 A1 5/2008 Gardette 8431560 B1 4/2013 Manku et al. 2008.0125490 A1 5/2008 Svensson et al. 8.440,650 Bi 52013 Manku et al. 2008. O1851.98 A1 8, 2008 Jones 8.518,929 B2 & 2013 Manku et al. 2008, 0200547 A1 8, 2008 Peet et al. 8,524.698 B2 9/2013 Manku et al. 2008/0200707 A1 8/2008 Shimano et al. 8,546.372 B2 10/2013 Manku et al. 2008/0299187 Al 12/2008 Opheim et al. 85.5521 B2 0/2013 Manku et al. 2008/0306154 A1 12/2008 Svensson et al. 8,563.608 B2 10/2013 Manku et al. 2008/0319077 A1 12/2008 Suzuki et al. 86,7593 B2 13/2013 Manku et al. 2009/0012167 A1 1/2009 Rongen et al. 8,617.594 B2 12/2013 Manku et al. 2009 OO18125 A1 1/2009 Mittmann et al. 8,623.406 B2 1/2014 Manku et al. 2009/0156675 A1 6/2009 Yokoyama et al. 8.642,077 B3 2/2014 Manku et al. 2009/0182049 A1 7/2009 Opheim 8,669,245 B2 3/2014 Osterloh et al. 2009.02276O2 A1 9, 2009 Griffin et al. 8,680.144 B2 3/2014 osterloh et al. 20090304784 A1 12/2009 Mane et al. 8,691.87 B2 4/2014 osterloh et al. 2009/0311322 A1 12/2009 Dlugatch et al. 8,703,185 B2 4/2014 Manku et al. 2010/0021555 A1 1/2010 Geiringer et al. 8,709.475 B2 4/2014 Manku et al. 2010.0063018 A1 3/2010 Pellicciari et al. 8,906,964 B2 12/2014 Bobotaset al. 2010/0069492 A1 3/2010 Geiringen et al. 2001 0035125 A1 11, 2001 Talieh et al. 2010.0113506 A1 5, 2010 Kawano et al. 2002fOO16312 A1 2/2002 Seed et al. 2010/0113811 A1 5, 2010 Yadav et al. 2002fOO25983 A1 2/2002 Horrobin 2010/01 19598 A1 5, 2010 Yoshinari et al. 2002.0035.125 A1 3, 2002 Shear 2010, O130608 A1 5/2010 Ryan et al. 2002/005.5529 A1 5/2002 Bisgaier et al.